Ulcavis (bismuth subcitrate) coated tablets 120 mg. №28

Description

Ulcavis (bismuth subcitrate) coated tablets 120 mg. №28

Composition

active substance: bismuth subcitrate;

1 film-coated tablet contains 120 mg of bismuth oxide in the form of bismuth tripotassium dicitrate (bismuth subcitrate);

Excipients: corn starch, povidone K-30, potassium polocryline, macrogol 6000, magnesium stearate;

film coating: opara II transparent (contains: polyvinyl alcohol, macrogol 4000, talc), titanium dioxide (E 171).

Dosage form

Film-coated tablets.

Main physical and chemical properties: from white to almost white, round, slightly biconvex tablets, film-coated, with a beveled edge.

Pharmacotherapeutic group

Remedies for peptic ulcer and gastroesophageal reflux disease. Bismuth subcitrate. ATX code A02B X05.

Pharmacological properties

This pharmacological drug Ulcavis coated tablets is included in the group of drugs that are used in the treatment of peptic ulcer and gastroesophageal reflux diseases.
Getting into the acidic environment of the stomach, the drug forms a protective film on the ulcerative surface or erosion.
This formation helps to heal the resulting wounds on the mucous membrane of the stomach and helps to protect against the influence of gastric juice, increasing the formation of prostaglandin E2.
This substance stimulates the formation of mucus and bicarbonates, the accumulation of epidermal growth factor in the affected area, reduces the activity of pepsin and pepsinogen.
The drug shows a pronounced bactericidal effect against Helicobacter pylori.
The active ingredient does not penetrate the walls of the gastrointestinal tract.
Only a small amount is found in the blood.
The drug is eliminated in urine and feces.

Indications

Ulcavis coated tablets is prescribed for the treatment and correction of the following conditions:

• peptic ulcer of the stomach and duodenum, including those caused by Helicobacter pylori (as part of anti-Helicobacter pylori therapy regimens);
• chronic gastritis and gastroduodenitis in the acute phase, including those caused by Helicobacter pylori.

Contraindications

The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
The drug is contraindicated for use in severe renal failure.
In pediatrics, the drug is used after 4 years.

Application during pregnancy and lactation

This drug is not recommended for pregnant women – only under strict indications determined by the attending physician.
If it is necessary to take the drug during breastfeeding, lactation is suspended.

Method of administration and dosage:

• adults and children over 14 years old take 1 tablet 4 times a day or 2 tablets 2 times a day 30 minutes before meals and at night;
• children aged 8 to 14 years old take 1 tablet 2 times a day 30 minutes before meals;
• children aged 4 to 8 years take 8 mg / kg / day, in accordance with body weight;
• children weighing 15 kg to 30 kg take 1 tablet a day 30 minutes before meals;
• children weighing more than 30 kg take 1 tablet 2 times a day 30 minutes before meals.

The course of treatment is 4-8 weeks. For at least the next 2 months, do not take bismuth-containing drugs.
In the presence of Helicobacter pylori, tetracycline is introduced into treatment regimens.

Overdose

In case of overdose, symptoms characteristic of renal failure may occur.

Side effects

The drug is usually well tolerated when used in the recommended doses.
Allergy may occur in case of individual intolerance. In particular, it can be observed:

• bowel movements are black;
• nausea, vomiting, constipation, diarrhea;
• rash, itching.